References
1. Gorwitz RJ, Kruszon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008;197:1226-1234.
2. Hidron AI, Edwards JR, Patel J, et al; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
3. Styers D, Sheehan DJ, Hogan P, et al. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006;5:2.
4. Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis 2009;48(4 suppl):S231-S237.
5. Shorr AF, Tabak YP, Killian AD, et al. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med 2006;34:2588-2595.
6. Noskin GA, Rubin RJ, Schentag JJ, et al. The burden of Staphylococcus aureus infections on hospitals in the United States: an analysis of the 2000 and 2001 Nationwide Inpatient Sample Database. Arch Intern Med 2005;165:1756-1761.
7. Ringberg H, Thorén A, Lilja B. Metastatic complications of Staphylococcus aureus septicemia. To seek is to find. Infection 2000;28:132-136.
8. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003;163:2066-2072.
9. del Rio A, Cervera C, Moreno A, et al. Patients at risk of complications of Staphylococcus aureusbloodstream infection. Clin Infect Dis 2009;48(4 suppl):S246-S253.
10. Dutta A. Metastatic methicillin-sensitive Staphylococcus aureus infection. South Med J 2011;104:355-357.
11. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002;34:1431-1439.
12. Willcox PA, Rayner BL, Whitelaw DA. Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs. QJM 1998;91:41-47.
13. Kaech C, Elzi L, Sendi P, et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 2006;12:345-352.
14. Fridkin SK, Hageman JC, Morrison M, et al. Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. Methicillin-resistant Staphylococcus aureus disease in three communities [published correction appears in N Engl J Med 2005;352:2362]. N Engl J Med 2005;352:1436-1444.
15. King MD, Humphrey BJ, Wang YF, et al. Emergence of community-acquired methicillin-resistantStaphylococcus aureus USA 300 clone as the predominant cause of skin and soft tissue infections. Ann Intern Med 2006;144:309-317.
16. Larsen A, Stegger M, Goering R, et al. Emergence and dissemination of the methicillin resistant Staphylococcus aureus USA300 clone in Denmark (2000-2005). Euro Surveill 2007;12:22-24.